MOUNTAIN VIEW, Calif.,
Oct. 2, 2015 /PRNewswire/ -- Alexza
Pharmaceuticals, Inc. (Nasdaq: ALXA) today announced two management
promotions. Catherine
McAuliffe has been promoted to the newly created position of
Vice President, Operations. In this new role, Ms. McAuliffe
will be responsible for site operations including facilities,
calibration, environmental health and safety, supply chain and
purchasing at Alexza. Stacy
Palermini has been promoted to Vice President,
Finance. In this new role, Ms. Palermini will have increased
responsibilities in managing the accounting, finance, treasury,
risk management and human resource functions at Alexza.
- Catherine McAuliffe has served
as Vice President, Operations since September 2015. Ms. McAuliffe previously served
as Alexza's Executive Director, Operations from 2014 to 2015, as
Senior Director, Operations from 2007 to 2014 and as Director,
Operations from 2004 to 2007. From 1996 to 2004, Ms. McAuliffe held
several positions at the Affymax Research Institute, the most
recent of which was Director, Facilities and EH&S. Ms.
McAuliffe holds a MS in Environmental Management from the
University of San Francisco and a BS in
Biology from San Jose State
University.
- Stacy Palermini has served as
our Vice President, Finance and Corporate Secretary since
September 2015. Ms. Palermini served
as Alexza's Executive Director, Finance from 2011 to 2015, as
Senior Director, Finance from 2007 to 2011, as Director, Finance
from 2005 to 2007, and as Controller from 2003 to 2005. From 1996
to 2003, Ms. Palermini held various positions of increasing
responsibilities in finance and accounting at various companies,
and worked nine years at PricewaterhouseCoopers, a public
accounting firm, prior to joining industry. Ms. Palermini received
a BS in accountancy from University of
Illinois.
About Alexza Pharmaceuticals, Inc.
Alexza Pharmaceuticals is focused on the research, development,
and commercialization of novel, proprietary products for the acute
treatment of central nervous system conditions. Alexza's
products and development pipeline are based on the
Staccato® system, a hand-held inhaler designed to
deliver a pure drug aerosol to the deep lung, providing rapid
systemic delivery and therapeutic onset, in a simple, non-invasive
manner. Active pipeline product candidates include AZ-002
(Staccato alprazolam) for the management of epilepsy in
patients with acute repetitive seizures and AZ-007 (Staccato
zaleplon) for the treatment of patients with middle of the night
insomnia.
ADASUVE® is Alexza's first commercial product and has
been approved for sale by the U.S. Food and Drug Administration,
the European Commission and in several Latin American
countries. Teva Pharmaceuticals USA, Inc., a subsidiary of Teva Pharmaceutical
Industries Ltd., is Alexza's commercial partner for ADASUVE in the
United States. Grupo Ferrer Internacional SA is Alexza's
commercial partner for ADASUVE in Europe, Latin
America, the Commonwealth of Independent States countries,
the Middle East and North Africa countries, Korea, Philippines and Thailand.
ADASUVE® and Staccato® are registered
trademarks of Alexza Pharmaceuticals, Inc. For more
information about Alexza, the Staccato system technology or
the Company's development programs, please visit
www.alexza.com.
Safe Harbor Statement
This news release contains forward-looking statements that
involve significant risks and uncertainties. Any statement
describing the Company's expectations or beliefs is a
forward-looking statement, as defined in the Private Securities
Litigation Reform Act of 1995, and should be considered an at-risk
statement. Such statements are subject to certain risks and
uncertainties, particularly those inherent in the process of
developing and commercializing drugs, including the ability of
Alexza and its partners, Teva and Ferrer, to effectively and
profitably commercialize ADASUVE, estimated product revenues and
royalties associated with the sale of ADASUVE, the adequacy of the
Company's capital to support the Company's operations, and the
Company's ability to raise additional funds and the potential terms
of such potential financings. The Company's forward-looking
statements also involve assumptions that, if they prove incorrect,
would cause its results to differ materially from those expressed
or implied by such forward-looking statements. These and other
risks concerning Alexza's business are described in additional
detail in the Company's Annual Report on Form 10-K for the year
ended December 31, 2014 and the
Company's other Periodic and Current Reports filed with the
Securities and Exchange Commission. Forward-looking statements
contained in this announcement are made as of this date, and the
Company undertakes no obligation to publicly update any
forward-looking statement, whether as a result of new information,
future events or otherwise.
Logo -
http://photos.prnewswire.com/prnh/20140121/SF49110LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/alexza-pharmaceuticals-announces-management-promotions-300152857.html
SOURCE Alexza Pharmaceuticals, Inc.